CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy Adult subjects with ...
Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing ...
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 ...
(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) announced positive topline results from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 oral ...
GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company focused on discovering and developing new treatments for Parkinson's disease, today ...
STEVENAGE, England--(BUSINESS WIRE)--Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain ...
(RTTNews) - Inozyme Pharma, Inc. (INZY), a clinical-stage biopharmaceutical company, on Friday, announced positive interim results from its phase Ib ENERGY 1 trial and Expanded Access Program (EAP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results